Parametric Portfolio Associates LLC Has $435,000 Stake in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN)

Parametric Portfolio Associates LLC increased its position in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) by 304.7% during the first quarter, according to its most recent 13F filing with the SEC. The fund owned 103,263 shares of the biopharmaceutical company’s stock after buying an additional 77,748 shares during the period. Parametric Portfolio Associates LLC’s holdings in Achillion Pharmaceuticals were worth $435,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of ACHN. Teza Capital Management LLC bought a new position in shares of Achillion Pharmaceuticals during the first quarter worth approximately $131,000. UBS Asset Management Americas Inc. boosted its position in Achillion Pharmaceuticals by 83.8% in the first quarter. UBS Asset Management Americas Inc. now owns 53,669 shares of the biopharmaceutical company’s stock valued at $226,000 after buying an additional 24,471 shares during the period. Canada Pension Plan Investment Board boosted its position in Achillion Pharmaceuticals by 4.7% in the first quarter. Canada Pension Plan Investment Board now owns 35,800 shares of the biopharmaceutical company’s stock valued at $151,000 after buying an additional 1,600 shares during the period. Wells Fargo & Company MN boosted its position in Achillion Pharmaceuticals by 11.9% in the first quarter. Wells Fargo & Company MN now owns 215,820 shares of the biopharmaceutical company’s stock valued at $908,000 after buying an additional 22,931 shares during the period. Finally, HealthInvest Partners AB acquired a new position in Achillion Pharmaceuticals during the first quarter valued at approximately $2,096,000. Institutional investors own 70.70% of the company’s stock.

Achillion Pharmaceuticals, Inc. (NASDAQ ACHN) opened at 4.67 on Friday. The stock’s 50 day moving average price is $4.45 and its 200 day moving average price is $4.16. Achillion Pharmaceuticals, Inc. has a 12-month low of $3.15 and a 12-month high of $9.49. The company’s market capitalization is $638.67 million.

Achillion Pharmaceuticals (NASDAQ:ACHN) last announced its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.16) EPS for the quarter, hitting analysts’ consensus estimates of ($0.16). During the same quarter in the prior year, the firm posted ($0.14) EPS. On average, equities research analysts anticipate that Achillion Pharmaceuticals, Inc. will post ($0.63) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This piece of content was first published by BNB Daily and is owned by of BNB Daily. If you are accessing this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark law. The correct version of this piece of content can be accessed at https://www.baseball-news-blog.com/2017/08/19/achillion-pharmaceuticals-inc-nasdaqachn-shares-bought-by-parametric-portfolio-associates-llc-updated-updated.html.

Several research firms recently commented on ACHN. BidaskClub upgraded Achillion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Wednesday. Zacks Investment Research cut Achillion Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, August 11th. Robert W. Baird lowered Achillion Pharmaceuticals from an “outperform” rating to a “neutral” rating and set a $5.00 price objective for the company. in a report on Thursday, August 10th. Maxim Group set a $7.00 price objective on Achillion Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, August 9th. Finally, Chardan Capital lowered their price objective on Achillion Pharmaceuticals from $5.00 to $4.00 and set a “neutral” rating for the company in a report on Wednesday, August 9th. Two investment analysts have rated the stock with a sell rating, three have assigned a hold rating and five have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of $8.25.

About Achillion Pharmaceuticals

Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.

Institutional Ownership by Quarter for Achillion Pharmaceuticals (NASDAQ:ACHN)

Receive News & Ratings for Achillion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply